Key facts
- It has raised $2.0M.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for ERAD Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ERAD Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ERAD Therapeutics
Developer of gene therapy treatments designed to address rare neurological and neuromuscular diseases. The company offers gene therapy platforms for neuromuscular conditions and a biomolecular platform targeting rare genetic disorders with neurological manifestations, enabling patients with rare neurological diseases to access targeted therapeutic approaches.
- Sector
- Healthcare
- HQ
- West End, NC, United States
- Founded
- 2014
- Employees
- 2
- Website
- eradtx.com/
- Ownership
- Privately Held (backing)
ERAD Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ERAD Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ERAD Therapeutics in its N-PORT filings yet. We sweep new filings monthly.